Researchers announced a breakthrough in treating autoimmune kidney disease, revealing that Otsuka’s sibeprenlimab treatment reduced toxic protein levels by over half in patients’ urine after nine months. The results exceeded interim goals for a Phase 3 study and outperformed a competitor’s treatment. While serious side effects were reported, they were less common than those experienced with the placebo.
Source: https://www.statnews.com/2025/06/06/otsuka-tops-vera-therapeutics-in-kidney-disease-study-showdown